Carcinoma of Unknown Primary: Integrating Timely Interventions and Molecular Advancements for Improved Outcomes

Carcinoma of unknown primary (CUP) is a diverse group of malignancies characterized by metastatic disease without an identified primary site. It typically presents with a poor prognosis due to widespread metastasis at diagnosis. This report discusses a 58-year-old female patient with advanced CUP and diffuse liver metastasis. Initially misdiagnosed with sciatica, her persistent upper abdominal pain led to further imaging, which revealed multifocal liver lesions, retroperitoneal lymphadenopathy, and small pulmonary nodules. While identifying the primary tumor, tumor markers indicated elevated alpha-fetoprotein (AFP) and carbohydrate antigen 19-9 (CA 19-9) with normal carcinoembryonic antigen (CEA). The initial liver biopsy revealed benign tissue, prompting a second biopsy due to the high index of suspicion for carcinoma based on imaging findings. Immunohistochemistry revealed poorly differentiated carcinoma positive for HER2 (3+) and other markers, suggesting HER2-directed therapy as a treatment option. Given her frailty and tumor burden, a multidisciplinary team recommended chemotherapy with carboplatin and gemcitabine, alongside supportive care measures. This case underscores the complexity of CUP workup and management, where a patient's clinical stability may necessitate prompt treatment over exhaustive diagnostics. Given its potential benefits, the decision to integrate next-generation sequencing (NGS) as part of the workup and therapy highlights the role of tailored treatment in CUP management. Collaborative, multidisciplinary approaches are crucial for developing effective treatment plans and providing optimal patient outcomes. Ongoing research is essential to enhance the understanding and treatment of CUP, ensuring continued adaptation to advancing therapeutic strategies in clinical practice.